Acute and long-term effects of brivaracetam and brivaracetam-diazepam combinations in an experimental model of status epilepticus. by Niquet, Jerome et al.
UCLA
UCLA Previously Published Works
Title
Acute and long-term effects of brivaracetam and brivaracetam-diazepam combinations in 
an experimental model of status epilepticus.
Permalink
https://escholarship.org/uc/item/8n81z9zk
Journal
Epilepsia, 58(7)
ISSN
0013-9580
Authors
Niquet, Jerome
Suchomelova, Lucie
Thompson, Kerry
et al.
Publication Date
2017-07-01
DOI
10.1111/epi.13787
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Acute and long-term effects of brivaracetam and
brivaracetam–diazepam combinations in an experimental
model of status epilepticus
*JeromeNiquet, *Lucie Suchomelova, *1Kerry Thompson, †Henrik Klitgaard, †AlainMatagne,
and *‡ClaudeWasterlain
Epilepsia, 58(7):1199–1207, 2017
doi: 10.1111/epi.13787
Jerome Niquet is an
associate researcher
at the Department of
Neurology, David
Geffen School of
Medicine at UCLA.
SUMMARY
Objective: To evaluate acute and long-term effects of intravenous brivaracetam
(BRV) and BRV + diazepam (DZP) combination treatment in a rat model of self-
sustaining status epilepticus (SSSE).
Methods: Rats were treated with BRV (10 mg/kg) 10 min after initiation of perforant
path stimulation (PPS) as early treatment; or BRV (10–300 mg/kg), DZP (1 mg/kg), or
BRV (0.3–10 mg/kg) + DZP (1 mg/kg) 10 min after the end of PPS (established SSSE).
Seizure activity was recorded electrographically for 24 h posttreatment (acute
effects), and for 1 week at 6–8 weeks or 12 months’ posttreatment (long-term
effects). All treatments were compared with control rats using one-way analysis of
variance (ANOVA) and Bonferroni’s test, or Kruskal-–Wallis and Dunn’s multiple
comparison tests, when appropriate.
Results: Treatment of established SSSE with BRV (10–300 mg/kg) resulted in dose-
dependent reduction in SSSE duration and cumulative seizure time, achieving statisti-
cal significance at doses ≥100 mg/kg. Lower doses of BRV (0.3–10 mg/kg) + low-dose
DZP (1 mg/kg) significantly reduced SSSE duration and number of seizures. All con-
trol rats developed spontaneous recurrent seizures (SRS) 6–8 weeks after SSSE,
whereas seizure freedom was noted in 2/10, 5/10, and 6/10 rats treated with BRV
200 mg/kg, 300 mg/kg, and BRV 10 mg/kg + DZP, respectively. BRV (10–300 mg/kg)
showed a dose-dependent trend toward reduction of SRS frequency, cumulative sei-
zure time, and spike frequency, achieving statistical significance at 300 mg/kg. Combi-
nation of BRV (10 mg/kg) + DZP significantly reduced SRS frequency, cumulative
seizure time, and spike frequency. In the 12-month follow-up study, BRV (0.3–10 mg/
kg) + low-dose DZP markedly reduced SRS frequency, cumulative seizure time, and
spike frequency, achieving statistical significance at some doses. Early treatment of
SSSEwith BRV 10 mg/kg significantly reduced long-term SRS frequency.
Significance: These findings support clinical evaluation of BRV for treatment of status
epilepticus or acute repetitive seizures.
KEYWORDS: Epilepsy, Antiepileptic drug, Seizures, Neuronal injury, Perforant path
stimulation.
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Status epilepticus (SE) is a serious and severe medical
emergency that is associated with high mortality and sub-
stantial morbidity among survivors.1–4 Poor outcome is cor-
related with the duration of seizure activity, as well as
patient age, diagnosis, and comorbidities.5 Current practice
and clinical guidelines thus recommend that treatment is ini-
tiated rapidly and continued until the seizures are con-
trolled.4,6–8 However, choice of treatment is limited by a
lack of high-quality, randomized, controlled trials, particu-
larly involving patients in the later stages of SE, due to
methodologic concerns.5 Effective management of SE thus
remains a clinical challenge, and there is a recognized need
for well-tolerated, fast-acting, and efficacious treatment
options.
Brivaracetam (BRV) is a selective, high-affinity ligand
for synaptic vesicle protein 2A (SV2A), which has been
approved as adjunctive treatment for focal (partial-onset)
seizures in adults with epilepsy. BRV is available as an
intravenous formulation, but is not approved for use in
patients with SE. However, the preclinical profile of
BRV9 indicates that it may have potential for the treat-
ment of acute seizures. Levetiracetam (LEV), another
SV2A ligand, was effective in a preclinical model of
self-sustaining status epilepticus (SSSE).10 BRV binds to
SV2A with a 15- to 30-fold higher affinity than LEV11
and has a differential interaction with SV2A.12 BRV
penetrates the brain faster than LEV in preclinical mod-
els.9 BRV also had higher potency and showed more
complete seizure suppression than LEV in a wide range
of animal models of epilepsy.13 BRV pre-treatment
inhibited kindling acquisition in a corneal kindling
model in mice at doses approximately 10 times lower
than those of LEV,13 suggesting potent antiepileptogenic
activity, which may be beneficial in reducing the conse-
quences of SE.
Preclinical studies also indicate that BRV has a rapid
onset of action, a key attribute for the treatment of acute
seizures. BRV penetrates the blood–brain barrier (BBB) fas-
ter than LEV due to its higher lipophilicity, leading to a fas-
ter onset of action in audiogenic mice.14 Physiology-based
pharmacokinetic modeling has predicted that BBB penetra-
tion by BRV would also be rapid in humans, with brain con-
centrations peaking within min of intravenous
administration.14 In support of this, a recent post hoc analy-
sis of phase III data has indicated that oral BRV has an early,
sustained onset of action in a subset of responders.15
We previously developed an experimental model of
SSSE induced by electrical perforant path stimulation
(PPS) in adult rats.16,17 Intermittent stimulation of exci-
tatory pathways above afterdischarge threshold for
30 min creates a reverberating limbic circuit in which
seizures are self-sustaining and continue for many hours
in the absence of further stimulation. Once established,
this process is refractory to diazepam (DZP) and pheny-
toin.16 This model can be used to study the effects of
acute treatment given either before or after the seizures
have become self-sustaining. Long-term effects of acute
treatment can also be evaluated, since most rats sub-
jected to SSSE develop chronic epilepsy characterized
by quantifiable spontaneous recurrent seizures (SRS).
The objective of the studies reported here was to investi-
gate the acute and long-term effects of treatment with BRV
in this SSSE model. Because benzodiazepines are well
established as the initial treatment of choice for SE,18,19 the
role of a new medication is likely to be as a second drug to
be administered simultaneously with a benzodiazepine or
immediately after failure of a benzodiazepine. Therefore,
we examined the effect on SSSE of BRV alone or in combi-
nation with DZP.
Methods
Animals
Male Wistar rats (Simonsen Laboratories, Gilroy, CA,
U.S.A.) aged 8–10 weeks and weighing 260–280 g at the
beginning of the study, were used. All studies were con-
ducted in accordance with the protocol approved by the Ani-
mal Care Committee of the Greater Los Angeles Veterans
Administration Health Care System.
Surgical implantation of stimulating and recording
electrodes
Using previously described methodology,17 rats anes-
thetized with ketamine (60 mg/kg; Hospira, San Jose, CA,
U.S.A.) and xylazine (15 mg/kg; Baxter, Deerfield, IL,
U.S.A.) were implanted with a bipolar stimulating electrode
into the angular bundle of the perforant path, and a bipolar
recording electrode into the granule cell layer of the ipsilat-
eral dentate gyrus. The depth of the electrodes was opti-
mized by finding the maximal population spike evoked
from the dentate gyrus by PPS.
Key points
• Intravenous brivaracetam (BRV) was evaluated in an
experimental rat model of self-sustaining status epilep-
ticus (SSSE)
• Acute treatment with BRV ≥100 mg/kg significantly
reduced SSSE duration
• Lower doses of BRV (0.3–10 mg/kg) were effective in
combination with low-dose diazepam (DZP) for acute
treatment of SSSE
• SSSE induction resulted in delayed development of
spontaneous recurrent seizures (SRS) in control rats
• Acute treatment of SSSE with BRV 300 mg/kg alone,
or BRV 1–10 mg/kg in combination with DZP, pre-
vented or reduced the frequency of SRS
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Induction of self-sustaining status epilepticus
SSSE was induced in the awake state by PPS deliv-
ered for 30 min with the following parameters: 10 s
20 Hz trains of 1 msec, 20 V pulses delivered every
minute together with continuous 2 Hz stimulation using
the same parameters, as described previously.16,17 Elec-
troencephalography (EEG) and behavioral observations
were made for 10 min after the end of PPS to verify
the presence of SSSE before any treatment was initi-
ated. Rats with population spike amplitude <2 mV and
those that did not develop SSSE were excluded from
the studies. Acute effects were evaluated by EEG
recordings made during the 24 h after PPS, whereas
long-term effects were investigated by continuous 1-
week EEG/video recordings made 6–8 weeks or 1 year
later. Behavioral effects of acute treatment were evalu-
ated qualitatively by observation.
Administration of study treatments
Rats were randomly assigned to treatment groups that
were matched by body weight. A commercial preparation of
DZP in 0.9% saline (Hospira) was used. BRV was dissolved
in 0.9% saline (Baxter). Treatments (0.5–0.8 ml) were
infused at 0.20–0.25 ml/min into a tail vein. Combination
treatments were administered as close to simultaneously as
possible. Control rats treated with saline were included in
all studies.
The effect of early treatment was investigated by admin-
istration of BRV 10 mg/kg 10 min after the initiation of
PPS. Long-term outcomes were evaluated 6–8 weeks after
induction of SSSE.
The effect of treatment on established SSSE was investi-
gated by administration of treatments 10 min after the end
of PPS. Acute effects were evaluated after treatment with
BRV 10, 20, 30, 100, 200, and 300 mg/kg; and BRV
10 mg/kg, DZP 1 mg/kg, and BRV + DZP combinations:
0.3 + 1, 1 + 1, 3 + 1, and 10 + 1 mg/kg. Long-term
effects were evaluated 6–8 weeks after treatment with BRV
10, 20, 30, 100, 200, and 300 mg/kg, DZP 1 mg/kg, and
BRV + DZP 10 + 1 mg/kg; and 12 months after BRV
10 mg/kg, DZP 1 mg/kg, and BRV + DZP combinations:
0.3 + 1, 1 + 1, 3 + 1, and 10 + 1 mg/kg. Each treatment
group included 3–10 rats.
Seizure monitoring and quantification
Electrographic activity from the dentate gyrus was
recorded using the Monitor 8.1 computer program (Stel-
late Systems, Montreal, QC, Canada). Seizures and
spikes were detected and counted off-line using Har-
monie Software (Stellate Systems) as described previ-
ously.20 Events were recognized as seizures if the mean
amplitude was 2.7 times baseline amplitude, minimum
frequency was 3 Hz, maximum coefficient of variation
was 70, and duration was at least 3 s. Events were rec-
ognized as spikes if the mean amplitude was 4 times
baseline amplitude. Seizure authenticity was verified by
manual review and video analysis.
End points for acute effects were the following: SSSE
duration (min) measured from treatment initiation to the
end of the last electrographic seizure; number of sei-
zures recorded from treatment initiation to 24 h post-
treatment; cumulative seizure time (min) defined as the
sum of all individual seizure durations; mean duration
of individual seizures (s); and spike frequency (Hz).
End points for long-term effects were the following: SRS
frequency per week; cumulative seizure time (min per
week); mean duration of individual seizures (s); spike fre-
quency (Hz); and seizure freedom. Calculation of mean
cumulative seizure time included rats with no observed sei-
zures (i.e., seizure time = 0).
Statistical analyses
Data were analyzed by one-way analysis of variance
(ANOVA) followed by Bonferroni’s test, or if data were not
normally distributed, ANOVA on ranks (Kruskal-Wallis
test) followed by Dunn’s multiple comparison test using
Sigma-Stat (Systat Software Inc, San Jose, CA, U.S.A.);
p < 0.05 was regarded as statistically significant.
Results
Evolution of self-sustaining status epilepticus
Intermittent PPS for 30 min induced SSSE in all con-
trol rats. Behavioral limbic seizures were accompanied by
high-frequency spikes, which were recognized as seizures
by the software. Between software-recognized seizures,
rats displayed less severe seizure behavior accompanied
by spikes.
Behavioral effects of treatment
Rats injected with BRV 0.3–30 mg/kg showed no
obvious behavioral changes. A dose of 100 mg/kg
resulted in muscle relaxation and sedation lasting 10–
15 min, with intact corneal reflex and tail pinch
response. Following administration of 200–300 mg/kg,
rats became unresponsive with loss of corneal reflex and
tail pinch response, but showed progressive recovery
over 1 h. Injection of DZP 1 mg/kg induced mild ataxia,
drowsiness, and muscle relaxation, which lasted for a
few min. The behavioral effects of combinations of BRV
0.3–10 mg/kg with DZP 1 mg/kg were similar to those
observed with DZP alone.
Effect of early treatment with brivaracetam
All 10 control rats developed SRS after 6–8 weeks, com-
pared with 7/10 rats who were treated with BRV 10 mg/kg
administered 10 min after initiation of PPS. Early treatment
with BRV 10 mg/kg significantly reduced SRS frequency
and cumulative seizure time versus control, but had no
effect on spike frequency (Table 1).
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Effect of treatment on established self-sustaining status
epilepticus
Acute effects of brivaracetam
BRV 10–300 mg/kg administered 10 min after the end of
PPS produced a dose-dependent reduction in both duration
of SSSE (Fig. 1A) and cumulative seizure time (Fig. 1B),
which was statistically significant versus control at doses
≥100 mg/kg. Mean (standard error of mean [SEM]) SSSE
duration was reduced from 999 (34) min in control rats to
583 (72) at BRV 10 mg/kg, 116 (13) at 20 mg/kg, 180 (17)
at 30 mg/kg, 50 (9) at 100 mg/kg, 72 (14) at 200 mg/kg,
and 13 (1) min at 300 mg/kg. Cumulative seizure time was
reduced from 467 (68) min in control rats to 323 (55) at
BRV 10 mg/kg, 71 (7) at 20 mg/kg, 97 (13) at 30 mg/kg,
24 (5) at 100 mg/kg, 25 (6) at 200 mg/kg, and 5 (1) min at
300 mg/kg.
Acute effects of brivaracetam–diazepam combinations
Combination of BRV (0.3–10 mg/kg) with 1 mg/kg DZP
markedly and significantly reduced SSSE duration
(Fig. 2A) and number of seizures (Fig. 2B) versus control
rats. SSSE lasted for 1,213 (94) min in control rats versus
897 (250) min with BRV 10 mg/kg alone, 628 (50) min with
DZP 1 mg/kg alone, and 97 (55) min following combination
of these two treatments. The number of seizures per 24 h
was reduced from 72.4 (6.4) for control rats to 49.4 (2.0)
with BRV 10 mg/kg, 55.0 (6.6) for DZP 1 mg/kg, and 6.8
(2.2) for combination treatment. The lowest dose of BRV
(0.3 mg/kg) in combination with DZP 1 mg/kg reduced
SSSE duration to 358 (194) min and number of seizures to
15.0 (6.0). All BRV–DZP combinations acted more rapidly
than either drug alone (Fig. 3). Reappearance of seizure
activity was observed 3–7 h posttreatment in rats treated
with DZP alone, but was not seen after combination therapy.
None of the treatments had a marked effect on spike fre-
quency or mean duration of individual seizures (Table S1).
Long-term effects of brivaracetam and brivaracetam–
diazepam combinations
Follow-up at 6–8 weeks. All control rats developed chronic
epilepsy 6–8 weeks after induction of SSSE, with a mean
(SEM) SRS frequency of 8.4 (3.0) seizures per week, cumu-
lative seizure time of 4.6 (1.2) min per week, and spike fre-
quency of 0.64 (0.12) Hz. Seizure freedom was noted in 2/
10 and 5/10 rats who were treated with BRV alone at doses
of 200 and 300 mg/kg, respectively, and 6/10 rats who
received combination therapy with BRV 10 mg/kg + DZP
1 mg/kg (Fig. 4D). There were no rats who were seizure-
free in the other treatment groups.
In rats treated with BRV, there was a trend toward dose-
dependent reduction of SRS frequency (Fig. 4A), cumula-
tive seizure time (Fig. 4B), and spike frequency (Fig. 4C),
which was statistically significant at the highest dose of
BRV (300 mg/kg), with mean (SEM) SRS frequency of 1.6
Table 1. SRS frequency, cumulative seizure time, spike
frequency, and seizure freedom rates 6–8 weeks after
treatment with BRV 10 mg/kg administered before the
establishment of SSSE
Mean (SEM)
Control
(n = 10)
BRV 10
mg/kg (n = 10)
SRS frequency/week 8.4 (3.0) 1.4* (0.4)
Cumulative seizure
time (min/week)
4.62 (1.18) 0.87* (0.31)
Spike frequency (Hz) 0.64 (0.12) 0.45 (0.13)
Seizure freedom, n (%) 0 3 (30)
ANOVA, analysis of variance; BRV, brivaracetam; SEM, standard error of
mean; SRS, spontaneous recurrent seizure; SSSE, self-sustaining status epilep-
ticus.
*p < 0.05, ANOVA on ranks and Dunn’s multiple comparison test.
Figure 1.
Duration of SSSE (A) and cumulative seizure time (B) during the
24 h following treatment of established SSSE with BRV 10–
300 mg/kg. *p < 0.05, **p < 0.01, ***p < 0.001 vs. control,
ANOVA on ranks and Dunn’s multiple comparison test. ANOVA,
analysis of variance; BRV, brivaracetam; SEM, standard error of
mean; SSSE, self-sustaining status epilepticus.
Epilepsia ILAE
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(0.6) seizures per week, cumulative seizure time of 1.0 (0.4)
min per week, and spike frequency of 0.14 (0.02) Hz, versus
control values of 8.4 [3.0], 4.6 [1.2], and 0.64 [0.12], respec-
tively. BRV had no effect on duration of individual seizures
(Table S2).
Treatment with BRV 10 mg/kg alone or DZP 1 mg/kg
alone had no significant effect on mean (SEM) SRS fre-
quency (8.3 [2.3] and 7.9 [1.9] seizures per week), cumula-
tive seizure time (5.2 [1.4] and 5.6 [1.7] min/week), or spike
frequency (0.33 [0.06] and 0.39 [0.07] Hz). However, the
combination of BRV 10 mg/kg and DZP 1 mg/kg signifi-
cantly (vs. control) reduced SRS frequency to 1.0 (0.5) sei-
zures per week, cumulative seizure time to 0.5 (0.3) min per
week, and spike frequency to 0.14 (0.03) Hz.
Spontaneous recurrent seizures at 12 months. In the 12-
month follow-up study, large variations in computer-
detected seizures within and between groups were noted;
consequently, the record was analyzed manually. BRV
10 mg/kg and DZP 1 mg/kg alone had no significant effect
on any parameter compared with control rats, whereas the
combination of BRV (0.3–10 mg/kg) with DZP 1 mg/kg
markedly reduced SRS frequency, cumulative seizure time,
and spike frequency, achieving statistical significance at
some doses (Table S3). Seizure freedom was noted at
12 months in 2/4 and 3/5 rats that received combination
therapy with BRV 1 mg/kg and DZP 1 mg/kg, and BRV
10 mg/kg and DZP 1 mg/kg, respectively. None of the rats
treated with BRV 10 mg/kg alone, DZP 1 mg/kg alone, or
other combinations of BRV and DZP were seizure-free at
12 months.
Discussion
The findings of this study in an experimental rodent
model of established SSSE showed that high-dose BRV,
and the BRV and DZP combination, acted rapidly with min-
imal adverse effects and reduced SSSE duration at least
ninefold compared to untreated rats.
Drug dosages in humans and rodents can be compared by
expressing them per body surface area.21,22 A suprathera-
peutic BRV single dose of 200 mg (approximately
2.86 mg/kg) is equivalent to a rodent dose of approximately
18.6 mg/kg. Therefore, BRV doses used in rodents in this
study are not far above the “human equivalent dose,” since
BRV 20 mg/kg reduced the mean duration of SSSE to
116 min and cumulative seizure time to 71 min, compared
with 999 and 467 min, respectively, in control rats.
Lower doses of BRV were markedly more effective when
administered in combination with DZP than either drug
administered alone. SSSE was terminated within approxi-
mately 1.5 h by the combination of BRV 10 mg/kg and
DZP 1 mg/kg, compared with a mean duration of >20 h in
control rats. Low doses of BRV (0.3–3 mg/kg) also signifi-
cantly reduced SSSE duration in a dose-dependent manner
when administered in combination with DZP. The fact that
two treatments that had no action when given alone were so
effective in combination suggests the possibility of a syner-
gistic interaction. Isobolographic analyses could have pro-
vided a more thorough assessment of any synergistic
interaction, but were beyond the scope of these studies.
Because BRV is a selective, high-affinity ligand for
SV2A11 and DZP acts as a positive allosteric modulator at
the c-aminobutyric acid (GABA)A receptor,
23 the molecular
mechanism of this interaction remains to be explained. In
humans, BRV weakly inhibits cytochrome P450 (CYP)
2C1924 and may thus increase plasma concentrations of
drugs metabolized by CYP2C19, such as DZP. Although
DZP is metabolized in rodents by other rodent-specific iso-
forms, for example, CYP2D1, studies in mice have shown
that BRV 14.7 mg/kg intraperitoneal produced a threefold
increase in DZP concentrations in both plasma and brain
Figure 2.
Duration of SSSE (A) and number of seizures (B) during the 24 h
following treatment of established SSSE with BRV 10 mg/kg, DZP
1 mg/kg, and BRV–DZP combinations. *p < 0.05 vs. control,
ANOVA and Bonferroni’s test. ANOVA, analysis of variance; BRV,
brivaracetam; DZP, diazepam; SEM, standard error of mean; SSSE,
self-sustaining status epilepticus.
Epilepsia ILAE
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(UCB, data on file). Currently available evidence indicates
that BRV has the same disposition in rats and mice (UCB,
data on file). It is thus possible that a pharmacokinetic drug–
drug interaction contributed to the observed greater effec-
tiveness of DZP when administered in combination with
BRV in the current study. However, since plasma
Figure 3.
Time course of status epilepticus
over 1 h intervals in rats with
established self-sustaining status
epilepticus (SSSE) treated with BRV
10 mg/kg, DZP 1 mg/kg, and BRV–
DZP combinations. BRV,
brivaracetam; DZP, diazepam.
Epilepsia ILAE
Figure 4.
SRS frequency (A), cumulative seizure time (B), spike frequency (C), and seizure freedom rates (D) 6–8 weeks after treatment of estab-
lished SSSE with BRV 10–300 mg/kg, DZP 1 mg/kg, and BRV–DZP combination treatment. *p < 0.05, **p < 0.01, ***p < 0.001 vs. con-
trol, ANOVA on ranks and Dunn’s multiple comparison test. ANOVA, analysis of variance; BRV, brivaracetam; DZP, diazepam; SEM,
standard error of mean; SRS, spontaneous recurrent seizure; SSSE, self-sustaining status epilepticus.
Epilepsia ILAE
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concentrations of BRV and DZP were not measured in this
study, the extent and influence of any pharmacokinetic
drug–drug interaction are not known.
The dose of DZP administered to rats in these studies
(1 mg/kg) can be related to the human equivalent dose
when expressed per body surface area and is the equiva-
lent of 11 mg DZP for a 70-kg human. This is lower
than the dose used to treat SE in humans (0.25–0.4 mg/
kg),6 and was ineffective when given alone in this
model. The dose of BRV that may be effective in clini-
cal SE is not known. The human BRV dose equivalent
to that successfully used in rats (0.3–10 mg/kg) in com-
bination with DZP is 0.46–1.54 mg/kg, or 33–108 mg
for a 70-kg human.21,22 This is close to the recom-
mended BRV dose range for adjunctive treatment of
focal seizures, which is 50–200 mg/day administered in
two equally divided doses (i.e., 25–100 mg twice daily).
However, this study was conducted in an experimental
model in rats, and caution is required in extrapolation of
the dose findings to the clinical situation. The small
number of rats in some treatment groups is a further
study limitation.
The mean duration of each seizure was unaffected by
treatment; this was expected given that this parameter is
frequently unchanged by the administration of antiepilep-
tic drugs (AEDs). LEV has previously been reported to be
effective in the acute treatment of DZP-resistant, estab-
lished SSSE in the model used in this study.10 Compared
with the effective doses of BRV reported here (≥100 mg/
kg), markedly higher, supratherapeutic doses of LEV were
required to significantly diminish (200 mg/kg) or abort
(500–1,000 mg/kg) seizures. This finding is consistent
with the higher potency and efficacy of BRV compared
with LEV seen in other animal models of epilepsy and
seizures.13 Although the combination of BRV + DZP has
not been evaluated in other animal models of seizures and
epilepsy, previous preclinical studies have confirmed that
LEV may act synergistically with the benzodiazepines,
clonazepam (CLZ), and DZP. Combination of LEV with
CLZ markedly enhanced its anticonvulsant potency in
audiogenic susceptible mice without any concurrent effect
on adverse effect potential or brain and plasma concentra-
tions of either drug.25 Further studies showed that LEV
markedly enhanced seizure suppression by CLZ in amyg-
dala-kindled rats,26 and by DZP in SSSE induced by
PPS.10
Data reported here support the clinical evaluation in a
randomized clinical trial of the addition of low doses of
BRV to standard benzodiazepine treatment for SE. Benzo-
diazepines are recommended as emergency first-line treat-
ment, with the goal of terminating seizure activity as soon
as possible, but limitations of this approach include signifi-
cant adverse effects4 and the rapid development of benzodi-
azepine pharmacoresistance during SE.6,27 In contrast, BRV
50–200 mg/day administered orally is effective and has a
good tolerability profile in adults with focal seizures,28–30
and intravenous BRV is well tolerated when given by bolus
or infusion, either initiated as a new treatment or switched
from oral BRV.31
Low-dose BRV monotherapy (10 mg/kg) was effective
in reducing the long-term effects of SSSE when adminis-
tered early, but showed no therapeutic benefit once SE
had become self-sustaining. Loss of potency with delayed
administration has also been reported in studies of DZP
and phenytoin,16 LEV,10 and lacosamide.32 Clinically,
early treatment is more effective than delayed treat-
ment,6,18 and a 1 h delay in AED treatment is associated
with poorer outcome.3 Efficacy of early treatment is of
limited clinical relevance, since treatment of established
SSSE more closely mimics the typical clinical situation.
Treatment is usually initiated when the patient arrives in
critical care, at which point the seizures may have been
present for min or hours.33 However, these observations
support potential consideration of BRV as an early treat-
ment option that could be administered in a pre-hospital
setting.
All control rats demonstrated SRS in EEG recordings
conducted continuously for 1 week after a latent phase,
indicating that SSSE had resulted in the development of
chronic epilepsy. Acute treatment of established SSSE
with a high dose of BRV (300 mg/kg) administered alone,
or lower BRV doses (1–10 mg/kg) given simultaneously
with DZP, reduced the frequency of SRS. Some of the
rats treated with BRV at doses of 200 or 300 mg/kg, and
half of those who received BRV 10 mg/kg with DZP,
showed no evidence of SRS at 6 weeks. Seizure freedom
was also noted at 12 months in some rats who received
BRV 1 or 10 mg/kg with DZP. However, it is not possible
to conclude whether the observed seizure freedom
resulted from a true antiepileptogenic effect, from the
reduction in duration and severity of SSSE resulting in
less brain damage and synaptic reorganization, or from a
combination of both factors. In addition, the rats were
only monitored for 1 week, which may not have been suf-
ficient to reliably detect a lowering of seizure frequency.
A further study limitation is the lack of rotarod test data
for the combination of BRV and DZP, and consequent
need for caution in assessing the safety of treatment.
Although these observations indicate that BRV may be
effective in reducing the long-term consequences of SE
when administered as an acute treatment, particularly in
combination with a benzodiazepine, more studies are
required to determine the clinical significance.
In conclusion, the high efficacy of BRV observed in this
study in an experimental model of SSSE, together with the
rapid brain penetration coupled with fast onset of action
observed in preclinical studies, and significant efficacy and
good tolerability profile in clinical studies, support further
evaluation of BRV as a potential treatment for SE or acute
repetitive seizures.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Table S1.Mean individual seizure duration and spike fre-
quency during the 24 h following treatment of established
SSSE with BRV 10 mg/kg, DZP 1 mg/kg, and BRV–DZP
combinations.
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Table S2.Mean individual SRS duration 6–8 weeks after
treatment of established SSSE with BRV 10–300 mg/kg,
DZP 1 mg/kg, and BRV–DZP combination treatment.
Table S3. SRS frequency, cumulative seizure time, mean
individual seizure duration, spike frequency, and seizure
freedom rates 12 months after treatment of established
SSSE with BRV 10 mg/kg, DZP 1 mg/kg, and BRV–DZP
combinations.
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